

important. PCR complements traditional serological and other detection methods by allowing discrimination between and detection of specific nucleic acid sequences. In viral hepatitis for example, PCR is used to distinguish between viremic and non-viremic infection, and to monitor viral replication in patients undergoing interferon therapy. However, PCR analysis of biological samples such as blood and other body fluids, is often unreliable due to the presence of amplification inhibitors. These inhibitors are often difficult to separate from the nucleic acids, requiring long and inconvenient purification procedures for their removal. Even then, amplification may be compromised.

The authors have developed a fast, safe and easy protocol to efficiently purify viral nucleic acids from serum for reliable PCR. It is shown, that the sensitivity of the PCR strongly depends on template quality and that our new extraction method provides better quality nucleic acids than standard acid-phenol extractions. Data are presented demonstrating that RNA from as little as 0.01 µl HCV (Hepatitis C virus) positive serum can efficiently be amplified after purification by our procedure. The new procedure combines the handling advantages of spin-column technology with the ability of silica to specifically bind nucleic acids. After sample lysis in a special lysis buffer containing a chaotropic salt, samples are loaded onto a spin-column by micro-centrifugation. Nucleic acids are selectively bound to a silica membrane, and contaminants are washed away by two brief washes. Purified nucleic acid is then eluted in water or buffer, ready for direct addition to the PCR reaction. Moreover, this new method requires less hands-on time, uses no organic solvents or alcohol precipitations and minimizes the danger of contamination by infectious agents. It is ideal for simultaneous handling of multiple samples, enabling the preparation of 24 samples within 30 min. So far the method has successfully been tested for samples as different as fresh, frozen or dried whole blood in the presence of all common anti-coagulants, plasma, serum, buffy coat, bone marrow, mucus, cell suspensions, urine and tissue.

Molecular typing and epidemiology of *Borrelia burgdorferi* sensu latu

B. Graf, M. Schuppler and U. Göbel

Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Hermann-Herder-Str. 11, D-79104 Freiburg (Germany)

Borrelia burgdorferi, the Lyme disease agent, has long been considered a homogeneous species. However, recent evidence based on DNA-DNA hybridization, RFLP-

analysis, plasmid profiles, comparative 16S rRNA analysis, and typing with different monoclonal antibodies has led to the separation into three species, namely *B. burgdorferi* sensu strictu, *B. garinii*, and *B. afzelii*.

Direct solid-phase sequencing of in-vitro amplified 16S rRNA gene fragments was used for the typing of 67 *Borrelia* strains isolated from ticks and patients. Biotinylated PCR products were bound on paramagnetic particles, single strands were generated by alkali treatment and isolated by magnetic separation. Single stranded DNA was sequenced by modified Sanger dideoxy nucleotide sequencing.

All isolates showed a species-specific epidemiological distribution. *B. afzelii* was predominantly found in skin biopsies, but was, however, rarely isolated from ticks. To see whether ticks were harboring more than one *Borrelia* species, we have developed several sets of species-specific amplification primers to test for the prevalence within different tick populations.

Detection of parvovirus B19 specific antibodies and DNA in sera of hemophiliacs

A. Große-Bley, A. M. Eis-Hübing, R. Kaiser, J. Oldenburg^a, H. H. Brackmann^a, T. F. Schwarz^b and K. E. Schneweis

Institut für Medizinische Mikrobiologie und Immunologie und ^aInstitut für Experimentelle Hämatologie und Transfusionsmedizin, Universität Bonn, Sigmund-Freud-Str., D-53127 Bonn, and ^bMax von Pettenkofer Institut für Hygiene und Medizinische Mikrobiologie, Universität München, München (Germany)

It is known that parvovirus B19 (B19) is transmitted to hemophiliacs by clotting factors prepared from human plasma. However, it is not clear whether B19 is also transmitted by the more recently used inactivated clotting factor preparations. Therefore, we investigated 69 hemophiliacs, mostly children, receiving only clotting factors treated for virus inactivation. 49 of them (71%) were B19 IgG-positive and 18 of the IgG positive hemophiliacs (37%) were also B19 IgM-positive. In contrast, out of 73 age-matched controls only 10 (13%) were IgG-positive, two of them being also IgM-positive. In hemophiliacs treated before 1984 with non-inactivated clotting factors, seroprevalence was very similar: 115/161 (71%) presented B19 IgG and 30/115 (26%) IgM antibodies as compared to their age-matched controls with 16/50 (32%) B19 IgG and no IgM antibodies. In 4 out of 30 IgM positive hemophiliacs, active B19